EASTMAN CHEMICAL CO EMN

Eastman Chemical’s latest 10-Q reads like the world’s most polite haemorrhage notice: $2.18 billion in revenue, $107 million in net income, and a polite quarterly loss in operating cash of $137 million. The company still has $566 million in cash and equivalents per the last 10-K, but the first quarter’s working-capital swing suggests the till door has been left ajar. Inventory jumped $119 million, capex clocked in at $103 million, and R&D swallowed another $60 million-all without a single press release explaining whether the stock-up was planned brilliance or panic buying. The filing cheerfully calls this “differentiated application development,” which is finance-speak for turning plastic pellets into profit only if the customers’ engineers don’t nod off mid-sales pitch. (source: 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/915389/000091538926000099/emn-20260331.htm)

Eastman is a global specialty chemicals shop that turns hydrocarbons into advanced materials for everything from phone cases to hot-fill beverage bottles. The company’s filing describes its “differentiated application development” as converting market complexity into growth opportunities by letting customers understand how Eastman’s polymers perform inside their own products. In practice, that means Eastman’s chemists are less “drums and beakers” and more “embedded engineering consultants” who help clients shave grams off a phone while keeping it drop-proof. The filing does not, however, say how many grams Eastman actually shaved off or how much extra margin that generated. (source: 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/915389/000091538926000099/emn-20260331.htm)

On the numbers sheet, Eastman’s balance sheet shows $15.22 billion in assets against $9.14 billion of liabilities, leaving shareholders with $6.01 billion of equity. The income statement shows $2.18 billion in revenue, $107 million in net income, and diluted EPS of $0.93 on 115 million shares. Cash from operations managed a rare minus sign at $137 million, while capex clocked in at $103 million and R&D at $60 million. Inventory grew $119 million in the quarter, so the company is either building for a demand surge or watching its warehouses slowly turn into the world’s most expensive ski chalet. (source: 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/915389/000091538926000099/emn-20260331.htm)

The easiest way to see Eastman’s daily pulse is the SEC’s company facts JSON feed, which collates the raw XBRL line items straight from the filings. It’s the plumbing behind every price-screen and risk model, yet it reads like a firehose of numbers with no narrative. If you want the colour, read the 10-Q’s segment footnotes, which at least name the end-markets: advanced materials, chemicals, and fibres. The JSON will happily tell you the exact cents per share; the footnotes may tell you why anyone should care. (source: SEC company facts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000915389.json)

What changed this fortnight? Not much that the filings didn’t already contain. Eastman released its first-quarter results on 30 April via an 8-K, and the 10-Q followed on 1 May with the usual gauntlet of numbers and footnotes. The conflict minerals filing on 29 May added another layer of disclosure theatre, while four separate Forms 4 on 3, 11, and 12 May showed insiders buying or selling shares faster than a filing server can cough. The net effect is a company still chugging along in specialty chemicals, still spending heavily on R&D, and still watching its cash machine wheeze like an old extrusion line that forgot to oil its bearings. (source: SEC EDGAR filings index, https://www.sec.gov/edgar/browse/?CIK=915389)

What remains unproven? Eastman’s “differentiated application development” sounds grand, but the filings don’t show how much new revenue it generated or how much margin it unlocked. The $60 million R&D line is a line item, not a product launch. Until Eastman quantifies the payoff, the story remains a hypothesis wrapped in a footnote. (source: 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/915389/000091538926000099/emn-20260331.htm) What would deepen the file? A segment-by-segment breakdown in the next 10-Q that ties “application development” to actual sales uplift, a cash-flow bridge that explains the working-capital swing, and a crystal-clear reason why inventory is up $119 million without a corresponding revenue surge. Until then, Eastman is running on footnotes and hope. (source: 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/915389/000091538926000099/emn-20260331.htm)